Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Triggiani D, Donghia R, Crudele L, Rinaldi R, Sabb C
Acetaminophen use was also linked to an increased risk of eczema and allergic conditions
Gu X, Tang J, Chen C
Genazzani and co-workers proposed that ALC acts through the opioidergic pathway and alters protein/hormone functions by acetylating -OH groups in amino acids like serine, threonine or tyrosine, thereby improving their functions
Finally, note that while Tirzepatide is not yet FDA approved for weight loss, only for Type 2 Diabetes (though it seems that some healthcare practitioners may be prescribing it off label,) the FDA approval for Wegovy as a weight-loss drug predicates risk on body size (allowing prescriptions to people with a BMI 27 kg/m2 or greater who have at least one "weight-related comorbidity" or any patients with a BMI of 30.) So approval (based on a risk/benefit analysis) is based on fatness alone for some patients, and for others based on the idea that health conditions that people of all sizes get are "weight-related." This follows another dangerous pattern of weight -stigma in healthcare - viewing people as less-valuable and their lives more riskable at higher weights
HOME | DIABETES EDUCATION | WEGOVY AND ULCERATIVE COLITIS: CAN IT MANAGE SYMPTOMS BETTER